Navigation Links
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting
Date:1/13/2011

PARSIPPANY, N.J., Jan. 13, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that new data from its Phase 3 bunionectomy study to evaluate the efficacy and safety of the intraoperative administration of EXPAREL™ (bupivacaine extended-release liposome injection) is being presented in a poster session (number AAOS7) at the 57th Annual Meeting of the Orthopaedic Research Society held from January 13-16, 2011 in Long Beach, California. Study results from this multicenter, randomized, double-blind, parallel-group, placebo-controlled bunionectomy trial demonstrate that the median time to first use of opioid rescue medication was 7.2 hours for patients treated with EXPAREL compared with 4.3 hours for patients treated with placebo (p<0.0001).

The Phase 3 trial studied 193 subjects in four U.S. centers to determine the safety and efficacy of a single administration of EXPAREL for prolonged postoperative analgesia in subjects undergoing first metatarsal osteotomy (bunionectomy).

Previously disclosed Phase 3 findings in this study showed EXPAREL met its primary endpoint, with a statistically significant reduction in area under the curve analysis (AUC) of the pain intensity numeric rating scale (NRS) scores in subjects receiving EXPAREL compared with placebo (p=0.0005) over the first 24 hours following surgery. EXPAREL is a novel long-acting, sustained-release analgesic formulation of bupivacaine HCl. Bupivacaine HCl is widely used for treating postsurgical pain.

Additional key findings from the Phase 3 study being presented include:

  • A larger percentage of patients treated with EXPAREL avoided opioid rescue medication during the first 24 hours after surgery compared to placebo (7% vs. 1%; p<0.05);
  • Statistically, significantly more patients treated with EXPAREL were pain-free at 2, 4, 8 and 48 hours compared to placebo (p<0.05);
  • Statistically, significan
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    2. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
    6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
    7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
    8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
    11. Optimer Pharmaceuticals Announces Key Additions to Management Team
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Nov. 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... of "Quality Affordable Healthcare Products®," today announced the closing ... the sale of 6,809,210 ordinary shares at a public ... exercise of the option to purchase up to an ... and Barclays Capital Inc., as representatives of the several ...
    (Date:11/26/2014)... , Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... , Chairman, Chief Executive Officer and President, will participate ... Conference at The New York Palace Hotel in ... at 11:30 am Eastern Time (ET). To ... conference call, go to the  Investor Relations  section of ...
    (Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
    Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
    (Date:11/27/2014)... DC (PRWEB) November 27, 2014 “LAB.C” was ... which features the latest and coolest technology products available to ... conducted the product review and shared with viewers ... for iOS and Android devices. , Consumers love portability and ... Their Cable Case for the iPhone5 and 5S has ...
    (Date:11/27/2014)... This is a professional and ... For an overview analysis, the report introduces Insulin ... structure, industry overview, policy analysis, and news analysis, ... covers information on policy, plans for Insulin Market ... much more. , This report also ...
    (Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
    (Date:11/27/2014)... 27, 2014 RBSEO Services, a ... engine optimization service just at $99. RBSEO Services ... cannot afford costly search engine optimization service. So, ... their affordablity and requirements into consideration. , ... it has not compromised with the service quality. ...
    (Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified Internet ... discount on PPC service. The discount will be available for ... on 1 December 2014 and remain valid until midnight of ... professional working at Ethane Web Technologies says, "This is a ... big discount would make the service quite affordable for them. ...
    Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
    ... Researchers aren,t sure why two conditions are connected , WEDNESDAY, ... likely to have heart attacks, a new study shows, but ... still unclear. , The incidence of heart attacks in people ... suffer the headaches, according to a report in the Feb. ...
    ... quarter of Ontario hospitals surveyed in a Queen,s University-led study ... that do exist have been tested. In addition, key players ... pandemic preparedness was inadequate., "It,s not good enough just to ... to know how well it will work in an emergency," ...
    ... DES PLAINES, Ill. , Feb. 10 ... for the ENA Leadership Conference to be held in ... All of ENA,s sponsors will be recognized at the upcoming ... Monster.com and Stryker; the Leadership Conference Sponsor, Physio-Control; and the ...
    ... , ... - Hiru Corporation (HIRU; www.hirucorporation.com ) and its European subsidiary ... about the MindUp and Sabera Ruzdijic,s patents. Dr. Sabera Ruzdijic ... cancer project. The other team leaders in MindUp Research project are ...
    ... February 10, 2010 The American Society ... as part of its program specifically dedicated to promoting ... practiced in the United States. The ASGE Endoscopy Unit ... guidelines on privileging, quality assurance, endoscopy reprocessing and CDC ...
    ... ... on celiac disease, one of the most common and under-diagnosed autoimmune diseases, it,s symptoms, and ... patients a year, one being day-time Emmy Award winner, Elisabeth Hasselbeck of ABC’s “The View”. ... (PRWEB) February 11, 2010 ...
    Cached Medicine News:Health News:Migraine Linked to Increased Heart Attack Risk 2Health News:Migraine Linked to Increased Heart Attack Risk 3Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 2Health News:Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference 3Health News:MindUp (HIRU) Patents in the World Patent Database 2Health News:MindUp (HIRU) Patents in the World Patent Database 3Health News:ASGE recognizes 32 endoscopy units for quality and safety 2Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: